Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.
Company Details
- Employees
- 15
- Address
- Somerville, Ma
- Phone
- (617) 229-6499
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- finchtherapeutics.com
- Keywords
- Manager jobs.
- HQ
- Somerville, MA
Finch Therapeutics Questions
Finch Therapeutics's helpline number is (617) 229-6499
Finch Therapeutics's website is finchtherapeutics.com
Finch Therapeutics's LinkedIn profile is https://www.linkedin.com/company/finch-therapeutics
Finch Therapeutics has
15 employees.
View email and phone details for 15
employees at Finch Therapeutics.
Finch Therapeutics's industry is
Biotechnology Research
Finch Therapeutics's top competitors are
Kaleido Biosciences,
Vertex Pharmaceuticals,
Sarepta Therapeutics,
Beam Therapeutics,
Openbiome Foundation,
Evelo Biosciences,
Vedanta Biosciences, Inc.,
Seres Therapeutics,
Tessera Therapeutics,
Sage Therapeutics.
Finch Therapeutics's support email address is info@finchtherapeutics.com
Finch Therapeutics's categories are Biotechnology Research
